$PLRZJun 17, 2026, 12:15 PMAI processed
PLRZ: U.S. patent application published for mucoadhesive nasal drug‐delivery platform
AI Summary
Polyrizon (PLRZ) had U.S. patent application US 2024/0358741 A1 published covering its Trap & Target mucoadhesive polymer platform for nasal drug delivery, describing compositions that form durable mucosal films to improve retention, sprayability and drug absorption. The filing frames use across sprays, gels and inhalation for delivery of anti-inflammatories, vaccines, biologics and other APIs, but the technology is preclinical and the publication is an application, not an issued patent.
Positives
- U.S. patent application published for Trap & Target mucoadhesive nasal delivery platform (US 2024/0358741 A1).
- Claims describe formulations that could increase nasal mucosal retention and improve drug absorption.
- Platform is described for multiple dosage forms (sprays, gels, inhalation), which could broaden potential applications.
Negatives
- Publication is a patent application, not an issued patent; claims may not be granted.
- Technology appears to be at preclinical/early stage with no clinical or commercial data cited.
- No near-term regulatory approvals or revenue impact disclosed.